Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma

Yang,Xiaojie; Zhang,Dong; Chong,Tie; Li,Youfang; Wang,Ziming; Zhang,Peng

doi:10.3892/ol.2018.7871

Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma

Authors:
- Xiaojie Yang
- Dong Zhang
- Tie Chong
- Youfang Li
- Ziming Wang
- Peng Zhang
View Affiliations

Affiliations: Department of Urology, Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7871
Pages: 4229-4234
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed in order to explore the association between the early metastasis of renal cell carcinoma (RCC) and biological markers of tumor cells. A total of 200 patients with RCC, who received a nephrectomy between January 2015 and October 2015, were enrolled in the present study, while 100 healthy patients served as controls. The expression of cytokeratin 19 (CK19), endoglin (CD105) and cluster of differentiation 146 (CD146) were detected using immunohistochemical staining and western blotting. All three markers were highly expressed in tumor tissues compared with adjacent normal tissues. Subsequently, an enzyme‑linked immunosorbent assay was used to detect the differential expression of CK19, CD105 and CD146. The results revealed that there was a statistically significant difference in the expression of CK19 and CD105 between the two groups (P<0.05), whereas CD146 did not exhibit a statistically significant difference. The results of further experiments revealed no significant difference between four time points (Q1, 1 day pre‑operation; Q2, 1 day post‑operation; Q3, 1 week post‑operation; and Q4, 1 month post‑operation). Then, subgroup analysis was performed based on whether patients were circulating tumor cell (CTC)‑positive or not, and the difference between the Q1 time point and other three time points (Q2‑4). The results revealed no difference between the CTC‑positive and ‑negative groups, and no difference between the time points Q1 and Q2. However, the expression of CK19 and CD105 exhibited a significant difference between CTC‑positive and CTC‑negative groups according to the difference between the time points Q1 and Q3. Furthermore, on the basis of the difference between Q1 and Q4, the expression of CK19, CD105 and CD146 were significantly different (P<0.05). Taken together, the results suggested that CK19, CD105 and CD146 markers of peripheral blood may be considered to be effective tools to evaluate the early metastasis in a CTC‑positive condition. CK19, CD105 and CD146 may be useful for CTC in evaluating the prognosis of patients with RCC, although a larger sample size is necessary for further investigation.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, Richie JP and de la Rosette JJ: A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol. 57:223–232. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ritchie AW and Chisholm GD: The natural history of renal carcinoma. Semin Oncol. 10:390–400. 1983.PubMed/NCBI
5	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th. Springer-Verlag; New York: pp. 547–560. 2009
6	Chin AI, Lam JS, Figlin RA and Belldegrun AS: Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 8:1–7. 2006.PubMed/NCBI
7	Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M and Lv GY: Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis. Clin Chim Acta. 448:161–169. 2015. View Article : Google Scholar : PubMed/NCBI
8	Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, et al: WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol. 31:1677–1682. 2007. View Article : Google Scholar : PubMed/NCBI
9	Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D and Georgoulias V: Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol. 16:240–246. 2005. View Article : Google Scholar : PubMed/NCBI
10	Quackenbush EJ and Letarte M: Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J Immunol. 134:1276–1285. 1985.PubMed/NCBI
11	Wong SH, Hamel L, Chevalier S and Philip A: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 267:5550–5560. 2000. View Article : Google Scholar : PubMed/NCBI
12	Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K and Lioyd RV: Endoglin (CD105): A review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 31:2283–2290. 2011.PubMed/NCBI
13	Nair S, Nayak R, Bhat K, Kotrashetti VS and Babji D: Immunohistochemical expression of CD105 and TGF-beta1 in oral squamous cell carcinoma and adjacent apparently normal oral mucosa and its correlation with clinicopathologic features. Appl Immunohistochem Mol Morphol. 24:35–41. 2016. View Article : Google Scholar : PubMed/NCBI
14	Lytras D, Leontara V, Kefala M, Foukas PG, Giannakou N, Pouliakis A, Dervenis C, Panayiotides IG and Karakitsos P: Microvessel landscape assessment in pancreatic ductal adenocarcinoma: Unclear value of targeting endoglin (CD105) as prognostic factor of clinical outcome. Pancreas. 44:87–92. 2015. View Article : Google Scholar : PubMed/NCBI
15	Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B and Rasmuson T: Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 97:706–710. 2006. View Article : Google Scholar : PubMed/NCBI
16	Dubinski W, Gabril M, Iakovlev VV, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A, et al: Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol. 43:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wang Z and Yan X: CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 330:150–162. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sers C, Riethmuller G and Johnson JP: MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res. 54:5689–5694. 1994.PubMed/NCBI
19	Takaha N, Taira E, Taniura H, Nagino T, Tsukamoto Y, Matsumoto T, Kotani T, Sakuma S and Miki N: Expression of gicerin in development, oncogenesis and regeneration of the chick kidney. Differentiation. 58:313–320. 1995. View Article : Google Scholar : PubMed/NCBI
20	Taira E, Kohama K, Tsukamoto Y, Okumura S and Miki N: Gicerin/CD146 is involved in neurite extension of NGF-treated PC12 cells. J Cell Physiol. 204:632–637. 2005. View Article : Google Scholar : PubMed/NCBI
21	Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American Society of Clinical Oncology, : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
22	Saloustros E and Mavroudis D: Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. Future Oncol. 6:209–219. 2010. View Article : Google Scholar : PubMed/NCBI
23	de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
24	Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 20:1223–1229. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et al: Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 30:525–532. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lianidou ES, Markou A and Strati A: The role of CTCs as tumor biomarkers. Adv Exp Med Biol. 867:341–367. 2015. View Article : Google Scholar : PubMed/NCBI
27	Volpe A and Patard JJ: Prognostic factors in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
28	Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al: Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158:1110–1122. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yu XF, Yang HJ, Lei L, Wang C and Huang J: CK19 mRNA in blood can predict non-sentinel lymph node metastasis in breast cancer. Oncotarget. 7:30504–30510. 2016.PubMed/NCBI
30	Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M and Pantel K: Full-length cytokeratin-19 is released by human tumor cells: A potential role in metastatic progression of breast cancer. Breast Cancer Res. 11:R392009. View Article : Google Scholar : PubMed/NCBI
31	Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B and Grundy RG: CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol. 124:99–110. 2012. View Article : Google Scholar : PubMed/NCBI
32	Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Ishikawa S and Wada H: Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: Comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer. 39:289–296. 2003. View Article : Google Scholar : PubMed/NCBI
33	Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni Z, Karakitsos P, Lazaris AC, Papachristodoulou A, Klonaris C and Gazouli M: Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer. 10:12–17. 2007. View Article : Google Scholar : PubMed/NCBI
34	Lei X, Guan CW, Song Y and Wang H: The multifaceted role of CD146/MCAM in the promotion of melanoma progression. Cancer Cell Int. 15:32015. View Article : Google Scholar : PubMed/NCBI
35	Wang W, Yang ZL, Liu JQ, Jiang S and Miao XY: Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. Tumour Biol. 33:173–182. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F and Chabannon C: CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 11:R12009. View Article : Google Scholar : PubMed/NCBI
37	Koyama Y, Okayama H, Kumamoto K, Saito K, Nakamura I, Ohki S and Takenoshita S: Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer. Exp Ther Med. 1:627–633. 2010. View Article : Google Scholar : PubMed/NCBI
38	Pires FR, Shih IeM, da Cruz Perez DE, de Almeida OP and Kowalski LP: Mel-CAM (CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol. 39:277–281. 2003. View Article : Google Scholar : PubMed/NCBI
39	Molnar B, Ladanyi A, Tanko L, Sréter L and Tulassay Z: Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 7:4080–4085. 2001.PubMed/NCBI
40	Brandt B, Junker R, Griwatz C, Heidi S, Brinkmann O, Semjonow A, Assmann G and Zanker KS: Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 56:4556–4561. 1996.PubMed/NCBI
41	Méhes G, Witt A, Kubista E and Ambros PF: Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 159:17–20. 2001. View Article : Google Scholar : PubMed/NCBI